Great report takeaway: Valuation range of A$0.016-A$0.021 per share
We continue to value Invion at A$0.016-A$0.021 per share
using a weighted DCF approach. Although Invion’s valuation
has retreated from the highs of 2021, along with the broader
biotechnology sector, we believe that Invion has the potential
to re-rate as the clinical development of INV043 de-risks its
future prospects. Please see page 11 for key risks.
Add to My Watchlist
What is My Watchlist?
